Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes

David E. Kelley, Pascual Bidot, Zachary Freedman, Burritt Haag, David Podlecki, Marc Rendell, David Schimel, Stuart Weiss, Terry Taylor, Alice Krol, James Magner

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

OBJECTIVE - To demonstrate the efficacy, tolerability, and safety of acarbose compared with placebo in patients with type 2 diabetes inadequately controlled with diet and insulin. RESEARCH DESIGN AND METHODS - A multicenter randomized double-blind placebo-controlled parallel-group comparison study was conducted. The trial was 26 weeks with a 2-week screening period and a 24-week period of treatment with acarbose or placebo, with forced titration from 25 mg t.i.d. to 50 mg t.i.d. after 4 weeks, and titration of 50 mg t.i.d. to 100 mg t.i.d. after 12 weeks based on glucose control. The dosage of insulin was to remain stable. The primary efficacy variable was mean change from baseline in HbA(1c), and secondary efficacy variables included mean changes in fasting and postprandial plasma glucose and triglyceride levels. RESULTS - The addition of acarbose to the treatment of patients receiving background insulin and diet therapy resulted in a statistically significant reduction in mean HbA(1c) of 0.69% compared with placebo. There were statistically significant reductions in postprandial plasma glucose and glucose area under the curve, and in postprandial serum triglyceride levels in the acarbose-treated patients. Gastrointestinal side effects were more frequently reported in the acarbose-treated patients. There were no significant differences in hypoglycemic events or liver transaminase elevations between groups. CONCLUSIONS - This study demonstrated that the addition of acarbose to patients with type 2 diabetes who are inadequately controlled with insulin and diet is safe and generally well tolerated and that it significantly lowers HbA(1c) and postprandial glucose levels.

Original languageEnglish
Pages (from-to)2056-2061
Number of pages6
JournalDiabetes Care
Volume21
Issue number12
StatePublished - 1998

Fingerprint

Acarbose
Type 2 Diabetes Mellitus
Insulin
Safety
Glucose
Placebos
Triglycerides
Diet
Diet Therapy
Transaminases
Hypoglycemic Agents
Area Under Curve
Fasting
Research Design
Liver
Therapeutics
Serum

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Kelley, D. E., Bidot, P., Freedman, Z., Haag, B., Podlecki, D., Rendell, M., ... Magner, J. (1998). Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care, 21(12), 2056-2061.

Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. / Kelley, David E.; Bidot, Pascual; Freedman, Zachary; Haag, Burritt; Podlecki, David; Rendell, Marc; Schimel, David; Weiss, Stuart; Taylor, Terry; Krol, Alice; Magner, James.

In: Diabetes Care, Vol. 21, No. 12, 1998, p. 2056-2061.

Research output: Contribution to journalArticle

Kelley, DE, Bidot, P, Freedman, Z, Haag, B, Podlecki, D, Rendell, M, Schimel, D, Weiss, S, Taylor, T, Krol, A & Magner, J 1998, 'Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes', Diabetes Care, vol. 21, no. 12, pp. 2056-2061.
Kelley DE, Bidot P, Freedman Z, Haag B, Podlecki D, Rendell M et al. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care. 1998;21(12):2056-2061.
Kelley, David E. ; Bidot, Pascual ; Freedman, Zachary ; Haag, Burritt ; Podlecki, David ; Rendell, Marc ; Schimel, David ; Weiss, Stuart ; Taylor, Terry ; Krol, Alice ; Magner, James. / Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. In: Diabetes Care. 1998 ; Vol. 21, No. 12. pp. 2056-2061.
@article{bcb7fa5af6074679ad117100d38a0692,
title = "Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes",
abstract = "OBJECTIVE - To demonstrate the efficacy, tolerability, and safety of acarbose compared with placebo in patients with type 2 diabetes inadequately controlled with diet and insulin. RESEARCH DESIGN AND METHODS - A multicenter randomized double-blind placebo-controlled parallel-group comparison study was conducted. The trial was 26 weeks with a 2-week screening period and a 24-week period of treatment with acarbose or placebo, with forced titration from 25 mg t.i.d. to 50 mg t.i.d. after 4 weeks, and titration of 50 mg t.i.d. to 100 mg t.i.d. after 12 weeks based on glucose control. The dosage of insulin was to remain stable. The primary efficacy variable was mean change from baseline in HbA(1c), and secondary efficacy variables included mean changes in fasting and postprandial plasma glucose and triglyceride levels. RESULTS - The addition of acarbose to the treatment of patients receiving background insulin and diet therapy resulted in a statistically significant reduction in mean HbA(1c) of 0.69{\%} compared with placebo. There were statistically significant reductions in postprandial plasma glucose and glucose area under the curve, and in postprandial serum triglyceride levels in the acarbose-treated patients. Gastrointestinal side effects were more frequently reported in the acarbose-treated patients. There were no significant differences in hypoglycemic events or liver transaminase elevations between groups. CONCLUSIONS - This study demonstrated that the addition of acarbose to patients with type 2 diabetes who are inadequately controlled with insulin and diet is safe and generally well tolerated and that it significantly lowers HbA(1c) and postprandial glucose levels.",
author = "Kelley, {David E.} and Pascual Bidot and Zachary Freedman and Burritt Haag and David Podlecki and Marc Rendell and David Schimel and Stuart Weiss and Terry Taylor and Alice Krol and James Magner",
year = "1998",
language = "English",
volume = "21",
pages = "2056--2061",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "12",

}

TY - JOUR

T1 - Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes

AU - Kelley, David E.

AU - Bidot, Pascual

AU - Freedman, Zachary

AU - Haag, Burritt

AU - Podlecki, David

AU - Rendell, Marc

AU - Schimel, David

AU - Weiss, Stuart

AU - Taylor, Terry

AU - Krol, Alice

AU - Magner, James

PY - 1998

Y1 - 1998

N2 - OBJECTIVE - To demonstrate the efficacy, tolerability, and safety of acarbose compared with placebo in patients with type 2 diabetes inadequately controlled with diet and insulin. RESEARCH DESIGN AND METHODS - A multicenter randomized double-blind placebo-controlled parallel-group comparison study was conducted. The trial was 26 weeks with a 2-week screening period and a 24-week period of treatment with acarbose or placebo, with forced titration from 25 mg t.i.d. to 50 mg t.i.d. after 4 weeks, and titration of 50 mg t.i.d. to 100 mg t.i.d. after 12 weeks based on glucose control. The dosage of insulin was to remain stable. The primary efficacy variable was mean change from baseline in HbA(1c), and secondary efficacy variables included mean changes in fasting and postprandial plasma glucose and triglyceride levels. RESULTS - The addition of acarbose to the treatment of patients receiving background insulin and diet therapy resulted in a statistically significant reduction in mean HbA(1c) of 0.69% compared with placebo. There were statistically significant reductions in postprandial plasma glucose and glucose area under the curve, and in postprandial serum triglyceride levels in the acarbose-treated patients. Gastrointestinal side effects were more frequently reported in the acarbose-treated patients. There were no significant differences in hypoglycemic events or liver transaminase elevations between groups. CONCLUSIONS - This study demonstrated that the addition of acarbose to patients with type 2 diabetes who are inadequately controlled with insulin and diet is safe and generally well tolerated and that it significantly lowers HbA(1c) and postprandial glucose levels.

AB - OBJECTIVE - To demonstrate the efficacy, tolerability, and safety of acarbose compared with placebo in patients with type 2 diabetes inadequately controlled with diet and insulin. RESEARCH DESIGN AND METHODS - A multicenter randomized double-blind placebo-controlled parallel-group comparison study was conducted. The trial was 26 weeks with a 2-week screening period and a 24-week period of treatment with acarbose or placebo, with forced titration from 25 mg t.i.d. to 50 mg t.i.d. after 4 weeks, and titration of 50 mg t.i.d. to 100 mg t.i.d. after 12 weeks based on glucose control. The dosage of insulin was to remain stable. The primary efficacy variable was mean change from baseline in HbA(1c), and secondary efficacy variables included mean changes in fasting and postprandial plasma glucose and triglyceride levels. RESULTS - The addition of acarbose to the treatment of patients receiving background insulin and diet therapy resulted in a statistically significant reduction in mean HbA(1c) of 0.69% compared with placebo. There were statistically significant reductions in postprandial plasma glucose and glucose area under the curve, and in postprandial serum triglyceride levels in the acarbose-treated patients. Gastrointestinal side effects were more frequently reported in the acarbose-treated patients. There were no significant differences in hypoglycemic events or liver transaminase elevations between groups. CONCLUSIONS - This study demonstrated that the addition of acarbose to patients with type 2 diabetes who are inadequately controlled with insulin and diet is safe and generally well tolerated and that it significantly lowers HbA(1c) and postprandial glucose levels.

UR - http://www.scopus.com/inward/record.url?scp=0031767296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031767296&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 2056

EP - 2061

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 12

ER -